Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acapella: PRAX-114 in Major Depressive Disorder
NCT04969510Phase 2Completed
- Sponsor
- Praxis Precision Medicines
- Start
- Jun 2021
- Primary completion
- Jul 2022
- Modality
- Allosteric Modulators
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of PRAX-114 in major depressive disorder (MDD) (5 arms), sponsored by Praxis Precision Medicines. Primary endpoint: Hamilton Depression Rating Scale 17-Item Total Score at Day 15. Started Jun 2021; status: completed.
02
Drugs
PRAX-114
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04969510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04969510.